Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SF3B1, RUNX1 and TP53 Mutations Significantly Impact the Outcome of Patients With Lower-Risk Myelodysplastic Syndrome.

Clinical lymphoma, myeloma & leukemia - 1 Dec 2022

Falantes Jose F, Márquez-Malaver Francisco J, Carrillo Estrella, Culebras Marta García, Morales Rosario, Prats Concepción, Vargas Maria T, Caballero Teresa, Rodríguez-Arbolí Eduardo, Espigado Ildefonso, Pérez-Simón Jose Antonio

Abstract excerpt

INTRODUCTION: Prognosis of patients with myelodysplastic syndrome (MDS), particularly the group with lower-risk disease (LR-MDS) is very heterogeneous. Several studies have described the prognostic value of recurrent somatic mutations in MDS including all risk categories. Recently, the incorporation of genomic data to clinical parameters defined the new Molecular International Prognostic Scoring System (IPSS-M)....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Core Binding Factor Alpha 2 Subunit
Share to Leukemia, Myelomonocytic, Chronic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Myelodysplastic Syndromes

Share to Phosphoproteins

Share to Prognosis

Share to RNA Splicing Factors

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 36117041
DOI: 10.1016/j.clml.2022.08.012

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SF3B1, RUNX1 and TP53 Mutations Significantly Impact the Outcome of Patients With Lower-Risk Myelodysplastic Syndrome.PMID 36117041Read ↗

Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes.Semantic proximity Read ↗

Mutation status and burden can improve prognostic prediction of patients with lower-risk myelodysplastic syndromes.Semantic proximity Read ↗

Molecular Data and the IPSS-R: How Mutational Burden Can Affect Prognostication in MDS.Semantic proximity Read ↗

Incorporation mutational profile might reduce the importance of blast count in prognostication of low-risk myelodysplastic syndromes.Semantic proximity Read ↗

Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation.Semantic proximity Read ↗

Critical Role of Molecular-Based Stratification in Low-Risk Myelodysplastic Syndrome with Direct Progression to Acute Myeloid Leukemia: A Case Report.Semantic proximity Read ↗

The spectrum of genetic mutations in myelodysplastic syndrome: Should we update prognostication?Semantic proximity Read ↗

[Molecular international prognostic scoring system for myelodysplastic syndromes].Semantic proximity Read ↗

New Insight Into the Biology, Risk Stratification, and Targeted Treatment of Myelodysplastic Syndromes.Semantic proximity Read ↗

Have we reached a molecular era in myelodysplastic syndromes?Semantic proximity Read ↗

Mutations and prognosis in myelodysplastic syndromes: karyotype-adjusted analysis of targeted sequencing in 300 consecutive cases and development of a genetic risk model.Semantic proximity Read ↗

Molecular landscape of myelodysplastic neoplasms in disease classification and prognostication.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.